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Ebola andMarburg hemorrhagic fevers (EHF andMHF) are caused by the Filoviridae family,
Ebolavirus and Marburgvirus (ebolavirus and marburgvirus), respectively. These severe
diseases have high mortality rates in humans. Although EHF and MHF are endemic
to sub-Saharan Africa. A novel filovirus, Lloviu virus, which is genetically distinct from
ebolavirus and marburgvirus, was recently discovered in Spain where filoviral hemorrhagic
fever had never been reported. The virulence of this virus has not been determined.
Ebolavirus and marburgvirus are classified as biosafety level-4 (BSL-4) pathogens and
Category A agents, for which the US government requires preparedness in case of
bioterrorism. Therefore, preventive measures against these viral hemorrhagic fevers
should be prepared, not only in disease-endemic regions, but also in disease-free
countries. Diagnostics, vaccines, and therapeutics need to be developed, and therefore
the establishment of animal models for EHF and MHF is invaluable. Several animal models
have been developed for EHF and MHF using non-human primates (NHPs) and rodents,
which are crucial to understand pathophysiology and to develop diagnostics, vaccines, and
therapeutics. Rhesus and cynomolgus macaques are representative models of filovirus
infection as they exhibit remarkably similar symptoms to those observed in humans.
However, the NHP models have practical and ethical problems that limit their experimental
use. Furthermore, there are no inbred and genetically manipulated strains of NHP. Rodent
models such as mouse, guinea pig, and hamster, have also been developed. However,
these rodent models require adaptation of the virus to produce lethal disease and do not
mirror all symptoms of human filovirus infection. This review article provides an outline
of the clinical features of EHF and MHF in animals, including humans, and discusses
how the animal models have been developed to study pathophysiology, vaccines, and
therapeutics.
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INTRODUCTION
The Family Filoviridae includes three accepted genera, Ebolavirus
(ebolavirus), Marburgvirus (marburgvirus), and Cuevavirus
(Figure 1) (Kuhn et al., 2011, 2013). Filoviruses are classified as
biosafety level 4 (BSL-4) agents because they cause severe hemor-
rhagic fevers in humans and non-human primates (NHPs) with
high case-fatality rates, ranging between 23 and 90% (Sanchez
et al., 2007). Each of the Marburgvirus and Cuevavirus genera
consists of a single species, Marburg marburgvirus and Lloviu cue-
vavirus, respectively. The genus Marburgvirus has two subspecies:
Marburg virus (MARV) and Ravn virus (RAVV). The genus
Ebolavirus is divided into five distinct species, Zaire ebolavirus
(Ebola virus, EBOV), Sudan ebolavirus (Sudan virus, SUDV), Tai
Forest ebolavirus (Tai Forest virus, TAFV), Bundibugyo ebolavirus
(Bundibugyo virus, BDBV), and Reston ebolavirus (Reston virus,
RESTV; Kuhn et al., 2013). EBOV is highly virulent to humans
and NHPs with a mortality rate of up to 90% in African epi-
demics. The case fatality rate of SUDV and BDBV is ∼50 and
25%, respectively; the only person known to have been infected
with TAFV survived. RESTV has been known to cause symp-
tomatic disease in NHPs but not in humans. Lloviu virus belong-
ing to the genus Cuevavirus was identified in the absence of
replicating isolates during an investigation of die-off bats in Spain
and the virulence for humans and NHPs has not been assessed
(Negredo et al., 2011).
Although there has been an increasing frequency of filovirus
outbreaks reported from endemic regions of Africa and Asia in
recent years, there are no licensed vaccines or effective therapeu-
tics for filovirus hemorrhagic fever.
The primary source of patients with filovirus hemorrhagic
fever was mainly linked to exposure to animal carcasses found
in the forest or to the putative bat reservoir, resulting in sub-
sequent transmission through direct person-to-person contact
(Leroy et al., 2004, 2009). Filoviruses enter the body via direct
contact with infectious blood and/or body fluids. After an incu-
bation period of 2–21 days, non-specific initial symptoms such
as fever, chills, fatigue, headache, and myalgia appear. About
5–7 days after onset, a maculopapular rash usually develops on
the face, buttocks, trunk, and/or arms and later generalizes over
the entire body. As disease progresses, systemic (prostration,
lethargy), gastrointestinal (anorexia, vomiting, abdominal pain,
diarrhea), respiratory (chest pain, breath shortness, cough, nasal
discharge), vascular (conjunctival injection, postural hypoten-
sion, edema), and neurological (headache, confusion, coma)
www.frontiersin.org September 2013 | Volume 4 | Article 267 | 1
Nakayama and Saijo Filovirus disease model
FIGURE 1 | Phylogenetic analysis of filovirus based on nucleotide
sequence. The phylogenetic tree based on complete viral genome
sequences was constructed by using the neighbor-joining method.
Numbers at branch points indicate bootstrap values (1000 replicates). The
GenBank accession numbers of Tai Forest virus (TAFV), Bundibugyo virus
(BDBV), Ebola virus (EBOV), Reston virus (RESTV), Sudan virus (SUDV),
Lloviu virus (LLOV), Marburg virus (MARV), and Ravn virus (RAVV) are
FJ217162, FJ217161, AF086833, AB050936, AY729654, JF828358,
DQ217792, and EF446131, respectively.
manifestations are observed. Some patients develop multiple
foci of mucosal hemorrhage, which is especially evident in
conjunctiva and gingiva together with bleeding from venipunc-
ture sites. Hemorrhagic symptoms observed during the peak of
the illness include petechiae, ecchymoses, epistaxis, mucosal hem-
orrhages, and/or visceral hemorrhagic effusions. In fatal cases,
patients die with hypovolemic shock and multiple organ failure
between Day 6 and 16.
Animal models of filovirus infection have been developed in
mice, guinea pigs, hamsters, and NHPs (Connolly et al., 1999;
Bente et al., 2009; Bradfute et al., 2012; Wahl-Jensen et al., 2012).
The development of animal models that accurately reflect human
disease is critical to understanding the pathogenesis of Ebola
and Marburg hemorrhagic fevers (EHF and MHF, respectively),
because filoviral outbreaks in humans are sporadic and there is
limited clinical data and access to human tissue. Since the wild-
type virus replicates to high titers in NHPs and the virus causes
symptoms, including hemorrhage and shock, which are simi-
lar to those of patients with EHF and MHF, NHP models may
be the most useful to evaluate the efficacy of candidate vaccines
and treatment measures. However, small animal models are also
needed for preliminary evaluation of vaccines and therapeutic
interventions against filovirus diseases, because of the ethical and
handling issues related to using NHPs.
Here, we summarize and discuss the animal models developed
for the study of hemorrhagic fever caused by filoviruses.
MOUSE MODELS
In contrast to the development of the NHP and guinea pig
models, as described in later sections, development of a mouse
model of filovirus infection has been unsuccessful due to the fact
that adult immunocompetent mice were resistant to wild-type
filovirus infection. The intraperitoneal or intracerebral inocula-
tion of newborn mice and 4-day-old suckling mice with non-
mouse adapted EBOV was shown to cause lethal infections, but
8-day-old or older mice did not show any symptoms (Johnson
et al., 1995; Bray, 2001). Serial passage of wild-type EBOV in
suckling mice was needed for adaptation, in which the virus
acquired lethal virulence to adult immunocompetent mice (Bray,
2001). Intraperitoneal inoculation of mouse-adapted EBOV with
a 1–100 plaque forming unit (pfu) dose (30–3000 times the
median lethal dose) caused lethal infection to 5-week-old BALB/c,
C57BL/6 and ICR (CD-1) mice, but subcutaneous inoculation of
the virus at a dose of 106 pfu did not cause symptomatic illness
in 3-week-old adult mice (Bray, 2001). This phenomenon is not
observed in NHP and guinea pig models, which are susceptible
to wild-type EBOV infection through any route of inoculation.
CD8+ T cells and perforin, but not B cells and CD4+ T cells,
are required for resistance to subcutaneous inoculation of EBOV
(Gupta et al., 2005). It is supposed that the presence of regional
lymph nodes and/or Langerhans cells in the skin contributes to
protection from filoviral subcutaneous infection via activation of
CD8+ cells, however, there are no reports to prove this hypothesis.
It has been shown that mouse-adapted filovirus is fatal over
a broad range of ages in BALB/c mice. Infected mice became
acutely ill with symptoms of ruffled fur, reduced activity, and
weight loss on Day 3–4 post-infection and died on Days 5–7,
although these lengths differed depending on the challenge dose
(Bray et al., 1999; Warfield et al., 2009). Virus titer in the liver and
spleen exceeded 107 pfu/g within 3 days after infection and then
reached a maximum of over 109 pfu/g at Day 5 post-inoculation.
These titers exceeded the peak viral concentrations in the liver
and spleen of infected guinea pigs (about 106 pfu/g) and NHPs
(about 107 pfu/g; Bray et al., 1999). The virus is generally unde-
tectable in serum on Day 1, but by Day 3 the viremia level peaks
at approximately 107 pfu/ml, which was comparable to that in
NHPs and exceeds that in guinea pigs (104−5 pfu/ml; Bray et al.,
1999).
As seen in the NHP model, the systemic viral spread results
in extensive infection and necrosis of the liver, spleen, and other
organs (Bray et al., 1999; Warfield et al., 2009). In liver from
mice infected with mouse-adapted EBOV or RAVV, viral repli-
cation was observed in hepatocytes, Kupffer cells, and sinusoidal
endothelial lining cells. Histological lesions were observed by Day
4 after inoculation, including coalescing, foci of hepatocellular
vacuolar change, degeneration, and necrosis of hepatocytes. In
the spleen, viral antigen was detected on Day 2 after infection,
at which point coagulopathy, such as disseminated intravascular
coagulation (DIC) accompanied by prolongation of prothrombin
time (PT) and activated partial thromboplastin time (aPTT), was
not observed in the moribund mice (Bray et al., 2001; Warfield
et al., 2009).
Mouse-adapted EBOV initially infects macrophages and other
mononuclear phagocytes at the site of invasion and in regional
lymph nodes. The major target cells of infection are as the
same as those in humans, NHPs, and guinea pigs (Davis et al.,
1997; Connolly et al., 1999; Zaki and Goldsmith, 1999; Gibb
et al., 2001). Viral replication in mononuclear phagocytes in the
lymph node, spleen, and thymus and an increase in the num-
ber of virus-infected Kupffer cells in the liver were observed by
Day 3 after infection. Most mononuclear phagocytes through-
out the body appear to be infected and the mice died by
Days 5–6.
The adaptation of EBOV to adultmice resulted in 8 amino acid
changes in both the coding and non-coding regions of the virus
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genome compared to the original wild-typed virus (Ebihara et al.,
2006). Nucleotide substitutions leading to amino acid changes
were found in VP35, VP24, NP, and L viral proteins. VP24 and
VP35 are known as type I interferon (IFN) antagonists and inter-
fere with type I IFN-mediated antiviral response in vitro (Bowen
et al., 1980; Basler et al., 2000; Bente et al., 2009; Halfmann et al.,
2011). VP24 functions as an IFN antagonist by binding karyo-
pherin α and blocking nuclear accumulation of signal transducer
and activator of transcription 1 (STAT1; Reid et al., 2007). VP35
is also implicated in blocking type I IFN responses by inhibit-
ing phosphorylation of interferon regulatory factor (IRF) 3 and 7
by the Tank binding kinase-1 and I-Kappa-B kinase epsilon, and
sequestering the viral RNA from detection by RIG-I like receptor
(Ramanan et al., 2011, 2012). It is considered that there is a sig-
nificant relationship between filoviral virulence and the ability of
the virus to evade the type I IFN-induced antiviral response (van
der Groen et al., 1979). The mutations in NP and VP24 genes
were found to be critical for acquisition of EBOV virulence in
adult mice, but not VP35 mutations (Ebihara et al., 2006). NP
is tightly coupled with viral RNA and forms the nucleocapsid
complex together with L, VP30, and VP35. Although it is unclear
how NP is involved in the IFN response, NP is thought to con-
fer evasion from the IFN-stimulated antiviral responses directly
or indirectly in infected mice.
The mutations identified for adaptation of marburgvirus to
mice differed from those required for that of ebolavirus. The
amino acid mutations were found in VP40, VP35, NP, and
VP30 in mouse-adapted RAVV compared to those of the wild-
type virus derived from a patient (Warfield et al., 2009). It
is still unclear what is the role and necessity of each of the
mutations in mouse-adapted RAVV. Further experiments are
required to clarify which mutations are critical for adaptation
to mice.
Adult mice treated with antibodies against IFN-α/β became
susceptible to infections with non-adapted EBOV or SUDV
infected via the intraperitoneal route, and tomouse-adapted virus
infected via the subcutaneous route (Bray, 2001). Furthermore,
non-adapted EBOV, SUDV,MARV, or RAVV caused illness in KO
mice lacking type I IFN receptors or the STAT1 protein (Bray,
2001). These results suggest that inhibition of type I IFN response
against filovirus infections is critical for pathogenesis in mouse
models.
Mice infected with the mouse-adapted filovirus are different
from humans and NHPs infected with the original filoviruses
in terms of a lack of severe coagulation disorder and fibrin
deposition. Mouse models are useful tools for studying basic
aspects of replication, pathogenesis, and immune responses and
also serve as an irreplaceable platform for evaluating the effi-
cacy of the wide range of the candidate vaccines and therapeutic
agents.
GUINEA PIG MODELS
Guinea pigs are susceptible to several arenaviruses, Lassa fever
virus, Junin virus, and Guanarito virus and used as animal mod-
els for human viral hemorrhagic fevers caused by these viruses
(Bowen et al., 1977; Jahrling et al., 1982; Kenyon et al., 1990; Hall
et al., 1996). However, infection of guinea pigs with wild-type
filovirus usually causes only a transient febrile illness (Simpson
et al., 1968; Robin et al., 1971; Bowen et al., 1977). Filoviruses
need to be serially passaged in guinea pigs to acquire the ability to
cause lethal infection in guinea pigs (Simpson et al., 1968; Robin
et al., 1971; Ryabchikova et al., 1996). Guinea pigs inoculated
with guinea pig (GP)-adapted virus showed similar symptoms
such as fever, anorexia, and dehydration, to those reported in
humans and NHPs infected with wild-type filovirus (Simpson
et al., 1968; Robin et al., 1971; Connolly et al., 1999). GP-adapted
EBOV-infected guinea pigs showed fibrin deposition coincident
with decreases in platelet count during the late stage of infection
(Connolly et al., 1999). GP-adapted EBOV replicated to high titers
in the spleen, liver, adrenal gland, and lung, resulting in viremia
in guinea pig models, although the peak titers were less than those
demonstrated in NHPs. Viremia in guinea pigs developed within
2 days after inoculation and increased during the course of the
disease, reaching a peak on Day 7 (>104 pfu/ml; Connolly et al.,
1999; Subbotina et al., 2010). The guinea pigs infected with the
GP-adapted filovirus died on 7–9 days after infection (Simpson
et al., 1968; Robin et al., 1971; Connolly et al., 1999; Subbotina
et al., 2010).
Histopathological changes in the liver of guinea pigs infected
with GP-adapted filoviruses included replication of the viruses
in Kupffer cells, multifocal necrosis of hepatocytes, and conges-
tion and destruction of the sinusoid wall, which were also similar
to those reported in humans and NHPs infected with wild-
type filoviruses (Korb and Slenczka, 1971; Connolly et al., 1999;
Ryabchikova et al., 2003). However, infiltrations of inflammatory
cells in the liver and other organs were mild or absent (Connolly
et al., 1999; Ryabchikova et al., 2003). Lymphoid necrosis
was observed in the spleen and lymph nodes of guinea pig
models.
Neutrophilia and lymphopenia became detectable in the
guinea pig model as early as 2 days after infection and the severity
continued to increase over the course of infection (Connolly et al.,
1999; Subbotina et al., 2010). However, lymphocyte bystander
apoptosis, an important feature in NHPs and mice, was not
prominent in guinea pigs (Bray et al., 1999; Connolly et al., 1999;
Bradfute et al., 2007). Thrombocytopenia was marked during
the late stages of the disease when guinea pigs became mori-
bund and platelets fell from a mean of ∼500,000 to <50,000/μl.
Fibrin deposition was a late event, beginning only modestly in
the liver and spleen on Day 4, with increases in distribution
and amount on Days 7–9, coincident with decreases in platelet
counts.
Comparative sequence analysis of the complete genomes of the
GP-adapted EBOV and wild-type virus showed 8 nucleotide dif-
ferences, which led to 5 amino acid substitutions; single amino
acid mutations in NP and L and 3 mutations in VP24 (Volchkov
et al., 2000). Using a reverse genetics approach, it was shown
that VP24 had a critical role in the pathogenesis and the amino
acid changes in VP24 were essential to achieve EBOV virulence
in guinea pigs. VP24 was demonstrated to antagonize IFN signal-
ing by binding host karyopherin α proteins and prevent transport
of the tyrosine phosphorylated transcription factor STAT-1 to
the nucleus (Reid et al., 2007; Mateo et al., 2010; Zhang et al.,
2012). One of the substitutions in VP24 of GP-adapted EBOV
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was located in the proximal domain, which was recently shown
to be involved in karyopherin binding and required for efficient
control of the IFN response (Mateo et al., 2010). However, the
mutations associated with EBOV adaptation to the guinea pigs
did not affect the ability of VP24 to inhibit IFN signaling (Mateo
et al., 2011). VP24 participates in the assembly and/or proper for-
mation of viral nucleocapsids. The lack of virulence of wild-type
virus in guinea pigs was associated with an inability of the virus to
replicate in and/or be released from hepatocytes andmacrophages
efficiently (Mateo et al., 2011). Wild-type VP24 is somehow
incapable of participating in assembly of viral nucleocapsids in
guinea pigs. Mutations in VP24 for adaption to guinea pigs
recovered the ability of EBOV to replicate in both macrophages
and hepatocytes and to facilitate the systemic spread of
the virus.
SYRIAN GOLDEN HAMSTER MODELS
The pathogenesis of rodent-adapted filoviruses differs in some
aspects from those of humans and NHPs infected with wild-typed
virus (Table 1). Fever and cutaneous rash, which are major clin-
ical signs of EHF and MHF in humans and NHPs, are absent
in mice infected with mouse-adapted virus. Fever appears in
guinea pigs infected with GP-adapted virus, but rash does not
develop in these animals.Mice infected with mouse-adapted virus
do not consistently display coagulation abnormalities. Compared
to mice, guinea pigs infected with GP-adapted virus develop
coagulation defects, including a drop in platelet counts and an
increase in coagulation time, but coagulopathy (i.e., DIC) are not
as marked as that observed in NHPs. Furthermore, lymphocyte
apoptosis observed in humans, NHPs, and mice was not deter-
mined in the guinea pig model. Because of these differences in the
rodent models, some vaccines (e.g., irradiated virion) and ther-
apeutics (e.g., passive immunization with antiserum) that were
effective in rodents challenged with adapted virus fail to pro-
tect NHPs challenged with wild-type virus (Wahl-Jensen et al.,
2012).
Moreover, in the guinea pig model, the lack of available
reagents and tools, such as quantitative reverse-transcription
polymerase chain reaction (qRT-PCR) and ELISA for cytokine
profiling, makes the guinea pig model less desirable. Therefore,
the development of other rodent models that better recapitu-
late EHF and MHF in humans was desired for more relevant
pathogenesis studies and high throughput screening of pro-
phylactic and post-exposure treatment prior to their testing
in NHPs.
Syrian golden hamster (Mesocricetus auratus) is broadly
used in animal models for human infectious diseases (Zivcec
et al., 2011). Suckling hamsters were susceptible to wild-type
MARV but disease was evident in only 40–80% of the ani-
mals following either intracerebral or intraperitoneal inocula-
tion (Zlotnik, 1971). The symptoms and the mortality which
was up to 90% were observed by inoculation with ninth pas-
sage materials in 5–6-week-old hamsters. While the patholog-
ical changes in the hamsters are similar to those observed
Table 1 | Comparison of pathological features of different animal models of filovirus infection.
Mouse Guinea pig Hamster NHP Human
Virus adaptation Adapted Adapted Adapted Wild-type Wild-type
Viremia High High High High Higha
Virulence High High High High Highb
Weight loss Severe Severe No Severe Severec
Rash No No No Yes Yesd
Thrombocytpenia Yes Yes Yes Yes Yese
Lymphocyte apoptosis Yes Limited Yes Yes Yesf
Cytokine response Yes Yes Yes Yes Yesg
PT Remained Increased Increased Increased Increasedh
PTT/aPTT Remained Increased Increased Increased Increasedi
TT ND ND Increased Increased ND
Fibrin deposition in organs Little Moderate Little Abundant Observedj
Protein C activity ND ND Decreased Decreased ND
aKsiazek et al., 1999; Ndambi et al., 1999; Sanchez et al., 2004; Towner et al., 2004; Kuhn, 2008.
bIsaacson et al., 1978; Piot et al., 1978; Smith et al., 1978; Bwaka et al., 1999; Sanchez et al., 2007; Kuhn, 2008.
cBwaka et al., 1999; Kuhn, 2008.
d Isaacson et al., 1978; Smith et al., 1978; Bwaka et al., 1999; Sanchez et al., 2007; Kuhn, 2008.
eSanchez et al., 2007; Kuhn, 2008.
f Baize et al., 1999.
gBaize et al., 1999, 2002; Sanchez et al., 2007.
hSanchez et al., 2007; Kuhn, 2008.
i Sanchez et al., 2007.
j Dietrich et al., 1978.
Abbreviation; PT, prothrombin time; PTT, partial thromboplastin time; APTT, activated partial thromboplastin time; TT, thrombin time ; ND, no data.
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in other animal models including patients, encephalitis, which
is not observed in other animals, were constantly demon-
strated in all suckling hamsters, irrespective of route of inoc-
ulation, and in adult hamsters, when the virus was inoculated
intracerebrally.
The Syrian golden hamster model was developed for EHF
based on infection with mouse-adapted EBOV. Six-week-old
hamsters infected intraperitoneally with 103 focus forming unit
(ffu) of mouse-adapted EBOV started to show clinical signs of
disease, including ruffled fur and decreased activity, by Day 3
after infection and succumbed to disease within 4–5 days after
infection. When inoculated subcutaneously, mouse-adapted virus
failed to produce lethal infection in hamsters in the same way
as the mouse model. Mouse-adapted EBOV-infected hamsters
showed severe coagulopathy with prolonged PT, aPTT, and
thrombin time (TT), in the late stage of infection (Ebihara et al.,
2013). Other factors, including increased fibrinogen, decreased
protein C activity, thrombocytopenia, and coagulation disor-
der were observed in the hamster model. The target organs
were the mesenteric lymph node, spleen, liver, and adrenal
gland. In the mesenteric lymph node, the target cells were the
macrophages and dendritic cells (DCs). The viral antigens were
found in macrophages, marginal reticular-like cells, and DC-
like cells in the spleen, and Kupffer cells and hepatocytes in
the liver. Histopathological changes, including inflammatory cell
infiltration, cellular necrosis, and apoptosis, were mainly noted
in the lymphoid organs (spleen and mesenteric lymph node) and
liver. These pathological changes were similar to those demon-
strated in NHPs and other rodent models (Baskerville et al., 1978;
Fisher-Hoch et al., 1992; Jahrling et al., 1996; Ryabchikova et al.,
1996, 1999; Bray et al., 1999; Connolly et al., 1999; Warfield
et al., 2009). Fibrin deposits in liver sinuses, which are a hall-
mark of EBOV infection in humans and NHPs, were detected
to a lesser extent in the hamster model (Ebihara et al., 2013).
Suppression of type I IFN that enhances viral replication in target
cells and contributes to lethal disease was observed (Ebihara et al.,
2013).
It has been demonstrated that the mouse-adapted EBOV-
based Syrian golden hamster model shows the most similar
clinical and pathological features, including coagulation abnor-
malities, to those observed in humans and NHPs infected with
wild-type EBOV.
NON-HUMAN PRIMATE MODELS
Although guinea pigs, mice, and hamsters models have been
developed to study EHF and MHF as stated above, the rodent
models are not ideal because mice and guinea pigs, except a
novel hamster model, do not entirely exhibit coagulation dis-
orders that are associated with human and NHPs filovirus
infections (Table 1). Additionally the bystander death of large
numbers of uninfected lymphocytes due to apoptosis that are
hallmark features in filovirus-infected humans and NHPs is
not present in infected guinea pigs. In mouse models, the
bystander lymphocyte apoptosis was reported, but the process
and morphology of lymphocyte apoptosis was different from
those of filovirus-infecting humans and NHPs (Bradfute et al.,
2007).
In NHP models, apoptosis was the primary reason for lym-
phocyte death, but the lymphocyte death in mouse models
appeared to occur by apoptosis and apoptosis-like programmed
cell death. Furthermore, NHPs are lethally infected with non-
adapted filovirus isolates resulting in pathophysiology similar to
that demonstrated in humans, although rodent models required
serial passages of the virus for adaptation to produce lethal
disease. Because of the aforementioned disadvantages and differ-
ences in the disease pathology, NHPs remain the most useful and
reasonable model of EHF and MHF despite practical and ethical
considerations leading to the restriction of experiments.
MARBURGVIRUS INFECTION IN NHPs
The first documented outbreak of MHF was associated with
wild-caught African green monkeys (Chlorocebus aethiops) in
Uganda and imported to Marburg and Frankfurt, Germany,
and to Belgrade, Serbia Montenegro, former Yugoslavia, in 1967
(Martini, 1971). Since the first outbreak of MHF originated
from the wild-caught African green monkeys, this species was
an obvious choice for an animal model of MHF. At that time,
rhesus macaques (Macaca mulatta) were found to be equally
susceptible to infection and showed symptoms after inoculation
with MARV (Hass and Maass, 1971). Cynomolgus macaques
(Macaca fascicularis) were also well characterized as an MHF
model (Hensley et al., 2011). After an incubation period of
2–6 days, the monkeys showed febrile illness, anorexia, diar-
rhea, skin rash, and hemorrhagic manifestations by any routes
of MARV-inoculation (Simpson et al., 1968; Simpson, 1969;
Murphy et al., 1971; Geisbert et al., 2007; Alves et al., 2010;
Hensley et al., 2011). Death occurred by 6–13 days post-infection
after a sudden decrease in body temperature and the mor-
tality rate was almost 100%. It was shown that reducing the
virus inoculum led to delayed onset of the disease and longer
time to death without reduction in mortality rate (Hass and
Maass, 1971). In the macaques, petechial rashes on the fore-
head, chest, axillae, and groins were prominent and resembled
the rashes that appeared in patients with MHF, but intriguingly
the rashes were not seen in African green monkeys (Simpson,
1969).
A marked lymphocytosis was observed at the beginning of
the illness (Simpson et al., 1968; Simpson, 1969; Gonchar et al.,
1991; Spiridonov et al., 1992; Johnson et al., 1996; Geisbert et al.,
2007). Thrombocytopenia and leukocytosis due to increased neu-
trophilia were prominent on 5–6 days after infection (Hensley
et al., 2011). Changes in coagulation systems, such as a decrease
in circulating levels of protein C, an increase in levels of circu-
lating D-dimer and fibrin deposition in tissues were noted at
late stages of the disease (Geisbert et al., 2007; Hensley et al.,
2011). The pathological changes in liver including multifocal
necrosis of the parenchyma cells, and lymphocyte apoptosis
in lymphoid tissues were prominent (Geisbert et al., 2000).
Monocyte/macrophages and DCs in the lymphoid tissues as well
as Kupffer cells and sinusoids lining cells in the liver were the
primary target cells for infections with MARV (Hensley et al.,
2011). The infection then progressed to parenchymal cells in the
liver, adrenal gland, and high endothelial venules in lymphoid tis-
sues. Finally, the infection spread to endothelial cells in a variety
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of organ tissues (Hensley et al., 2011). The virus or viral anti-
gen was detected in liver, lymph nodes, spleen, adrenal grand,
kidney, and blood in infected cynomolgus macaques. Onset of
viremia occurred on Day 3, and in cynomolgus macaques and
African green monkeys the maximum titer was 107−8 pfu/ml on
Day 8 after infection (Hass and Maass, 1971; Hensley et al.,
2011).
Under experimental conditions, the possibility of aerosol
transmission of MARV was shown in macaque models,
although such a transmission route has not been described
in human outbreaks (Pokhodiaev et al., 1991; Alves et al.,
2010).
EBOLAVIRUS INFECTION IN NHPs
African green monkeys, cynomolgus macaques, rhesus macaques,
and hamadryas baboons (Papio hamadryas) have been employed
as a model of EBOV infection (Baskerville et al., 1978, 1985;
Bowen et al., 1978, 1980; Ellis et al., 1978; Fisher-Hoch et al.,
1985, 1992; Johnson et al., 1995; Jaax et al., 1996; Jahrling et al.,
1996; Davis et al., 1997; Ryabchikova et al., 1999; Ignatiev et al.,
2000; Geisbert et al., 2003b,e). The monkeys infected with EBOV
became febrile 3 days after infection with temperatures above
40◦C. Pyrexia usually persisted throughout the course of the
disease, which usually ended in a decrease in temperature fol-
lowed by death, which occurred within 5–8 days after infection
(Baskerville et al., 1978; Bowen et al., 1978, 1980; Ellis et al.,
1978; Fisher-Hoch et al., 1985; Luchko et al., 1995). By Day 4,
anorexia developed with a loss of drinking ability, causing severe
weight loss and dehydration. Some monkeys that survived until
Day 5 had diarrhea, rectal bleeding, and/or intermittent melena.
Petechial skin rashes appeared on the forehead, fore and hind
limbs, and chest 4–5 days post-infection in macaques, but on Day
7 in baboons (Bowen et al., 1978; Ellis et al., 1978; Luchko et al.,
1995; Ignatiev et al., 2000; Geisbert et al., 2003b). African green
monkeys did not develop the cutaneous rash as demonstrated in
monkeys infected with MARV (Simpson, 1969; Baskerville et al.,
1978). Viremia became detectable within 3 days after infection
with the maximum virus titer at the level of 106.5−7 pfu/ml on
Day 4–5 (Bowen et al., 1978; Fisher-Hoch et al., 1992; Jahrling
et al., 1996; Geisbert et al., 2003b). The virus was positive in liver,
spleen and lung on Day 4 and also appeared to have lower affin-
ity for kidney, adrenal, lung, testis, lymph node, and pancreas
(Baskerville et al., 1978, 1985; Bowen et al., 1978; Geisbert et al.,
2003b). Mean virus titers in these organs increased progressively
and reached the highest level of 105.5−8.6 pfu/g on Day 6 (Geisbert
et al., 2003b).
Total blood cell counts revealed marked neutrophilia and
lymphopenia in the monkeys. Neutrophils and immature neu-
trophils increased remarkably by Day 4 (Fisher-Hoch et al.,
1985; Geisbert et al., 2003b; Ebihara et al., 2011). Coincident
with this process, severe lymphopenia due to lymphocyte apop-
tosis developed by Day 3 (Fisher-Hoch et al., 1985; Geisbert
et al., 2003b). Extensive lymphocyte apoptosis, both in the vas-
culature and in lymphoid tissue, appears to be critical to the
pathogenesis of EHF. Especially within the CD8+ subset, the
NK cell population dropped dramatically in the early stage
of infection (Geisbert et al., 2003b). Lymphocytes were not
productively infected and the apoptosis was not associated with
direct viral infection (Geisbert et al., 2000). However, the mech-
anism underlying such apoptosis is unclear. Another character-
istic feature was the abnormality of platelet function preced-
ing thrombocytopenia (Fisher-Hoch et al., 1985; Geisbert et al.,
2003b). Thrombocytopenia developed between 3 and 4 days and
abnormalities in coagulation parameters, including prolonged
PT, aPTT, and TT appeared (Geisbert et al., 2003b; Ebihara
et al., 2011). Examination of coagulation parameters revealed
that decreased protein C coagulation inhibitor activity due to
excessive consumption triggered severe coagulopathy as indicated
by prolonged coagulation times and decreased fibrinogen levels
(Ebihara et al., 2011).
The NHP model has been proven to be valuable in pro-
viding new information regarding filoviral pathogenesis. EBOV
spreads from the initial infection site via monocytes/macrophages
and DCs to regional lymph nodes, likely via lymphatics, and to
liver and spleen through the blood stream. Tissue macrophages,
including Kupffer cells, DCs, and fibroblastic reticular cells
become infected with EBOV at this stage. EBOV activates DCs
by upregulating expression of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL), which is expressed on DCs
and mediates their cytotoxic activity (Geisbert et al., 2003b).
Such overexpression of TRAIL is enhanced by overexpression of
IFN-α in NHPs infected with EBOV and triggers lymphocyte
apoptosis. Monocytes/macrophages infected with EBOV release
various soluble factors including proinflammatory cytokines to
recruit additional target cells to areas of infection. As disease pro-
gresses, increased levels of oxygen free radicals (e.g., nitric oxide)
released from virus-infecting macrophages at the inflammatory
sites trigger apoptosis of NK cells. The lymphocyte apoptosis
caused by TRAIL and nitric oxide interferes with the innate
immune response, resulting in escape of EBOV infection from
mounting an adaptive response. Coagulation abnormalities are
not the direct result of EBOV replication-induced cytolysis of
endothelial cells, but are likely triggered by immune-mediated
mechanisms (Geisbert et al., 2003d,e). Extensive viral replication
leads to increased levels of additional proinflammatory cytokines,
notably IL-6, which triggers the coagulation irregularities. This is
probably through upregulation of tissue factor expression/release
from virus-infected monocytes/macrophages. Tissue factor works
as the primary cellular inhibitor of coagulation protease cascades.
Activation of the coagulation cascade induces the fibrinogenic
and fibrinolytic pathways and finally leads to DIC, hemorrhagic
shock, thrombosis-related organ failure and death (Arai et al.,
2000).
Monkey species-specific disease features of the pathogenesis
of EBOV infection were observed, not only in the development
of cutaneous rash but also in the impairment of the clotting
systems of African green monkeys and baboons infected with
EBOV. In African green monkeys, fibrin thrombosis was gen-
eralized in all visceral organs, while in baboons hemorrhages
were prominent in visceral organs, most notably in the liver
and spleen (Ryabchikova et al., 1999; Ignatiev et al., 2000).
Genetic differences, even among the same animal species, and
the origin of a species may influence disease presentation and
progression.
Frontiers in Microbiology | Virology September 2013 | Volume 4 | Article 267 | 6
Nakayama and Saijo Filovirus disease model
The dose and species of challenge virus affects the progression
of disease. Intramuscular inoculation of cynomolgus macaques
with 103 pfu of EBOV produced a 100% lethal infection, with
deaths occurring 6–7 days post-infection (Geisbert et al., 2002).
When the challenge dose was lowered to 10 pfu, uniform lethality
was still achieved, but deaths occurred 9–12 days post-infection
(Geisbert et al., 2003c). Viremia was demonstrated as early as
24 h after subcutaneous infection of rhesus macaques with a high
infectious dose (105 pfu) of EBOV. In rhesus and cynomolgus
macaques infected with 103 pfu of EBOV, viremia is first detected
by Day 3 after infection. SUDV causes slower disease progres-
sion than EBOV and it has been reported that some monkeys
infected with SUDV did not die and recovered from the ill-
ness (Ellis et al., 1978; Bowen et al., 1980; Fisher-Hoch et al.,
1992). One of four rhesus macaques infected with SUDV died
on Day 12 but the other macaques survived and remained nor-
mal thereafter (Ellis et al., 1978). The dead macaque had small
numbers of virus particles in the liver but no virus particles
were found in the kidney, spleen, heart, lung, and brain. The
liver, lung, and spleen from EBOV infected macaques, which
were moribund and killed on Day 6 contained large numbers of
virions. The apparent limitation of viral replication in the liver
of SUDV-infected host and the contrasting widespread involve-
ment of liver and other organs such as the spleen and lung of
EBOV-infected host are similar in patients andmacaques. RESTV,
which is considered not to be virulent to humans, is clearly less
pathogenic than EBOV and SUDV in African green monkeys and
cynomolgus macaques (Fisher-Hoch et al., 1992; Jahrling et al.,
1996). Only 5 of 16 monkeys infected with EBOV or SUDV sur-
vived, whereas 11 of 15 monkeys infected with RESTV survived
(Fisher-Hoch et al., 1992). Viremia, clinical signs (temperature
rise, anorexia, depression, or evidence of disturbed hemostasis),
serum chemistry changes (elevated aspartate aminotransferase
and lactate dehydrogenase activities) and pathological changes
(necrosis of hepatocytes, adrenalcytes, and lymphoid elements
of the spleen and prominent fibrin thrombi and fibrin precip-
itation) in RESTV infected monkeys developed slower and/or
milder than those observed in monkeys infected with EBOV
and/or SUDV.
Most human cases are thought to occur by direct contact
with blood and/or body secretions from patients or animal
cadavers. Aerosol transmission among humans has not been
reported. However, evidence of intercage transmission of RESTV
was observed in the 1989–1990 epizootic cases of RESTV in
the Hazleton facility in Reston, Virginia, and demonstration of
high concentrations of ebolavirus in nasal secretions and alve-
oli in experimental infection implicated the potency of aerosol
transmission of ebolavirus (Baskerville et al., 1978, 1985; Bowen
et al., 1978; Jahrling et al., 1990, 1996; Dalgard et al., 1992; Jaax
et al., 1995; Miranda et al., 1999, 2002). Furthermore, the rhe-
sus macaques experimentally challenged with aerosolized EBOV
developed the same disease as macaques infected parenterally
(Johnson et al., 1995). Regardless of the route of infection (intra-
muscular, subcutaneous, conjunctival, and aerosol injections),
NHPs are highly susceptible to EBOV infection (Baskerville et al.,
1978; Bowen et al., 1978, 1980; Ellis et al., 1978; Baskerville
et al., 1985; Fisher-Hoch et al., 1985, 1992; Johnson et al.,
1995; Jaax et al., 1996; Jahrling et al., 1996; Davis et al., 1997;
Ryabchikova et al., 1999; Ignatiev et al., 2000; Geisbert et al.,
2003b,e).
VACCINES
INACTIVATED WHOLE VIRION
The development of filovirus vaccines has been performed based
on inactivated whole virion preparations. About half of the
rhesus macaques or African green monkeys treated were pro-
tected against homologous MARV challenge, when formalin- or
gamma-inactivated whole MARV virions were used as vac-
cine candidates (Ignat’ev et al., 1991; Ignatyev et al., 1996).
Vaccination with formalin-inactivated EBOV virions protected
4 of 5 hamadryas baboons (Mikhailov et al., 1994), while
other studies suggested that inactivated virus did not induce
sufficient immunity to protect baboons against a lethal chal-
lenge (Chupurnov et al., 1995). Furthermore, vaccination with
gamma-irradiated EBOV virions alone or in a form of liposomes
containing lipid A failed to protect cynomolgus macaques against
lethal infection (Geisbert et al., 2002). Overall, these vaccine can-
didates based on inactivated virions did not confer sufficient pro-
tection in NHP models. Furthermore, these vaccines are unlikely
to be used in humans due to safety risk of incomplete inacti-
vation. However, these results promoted the development of an
alternative vaccine platform, such as DNA-based vaccines, recom-
binant viral vector, or virus-like particles as described below and
Table 2.
VENEZUELAN EQUINE ENCEPHALITIS VIRUS REPLICON
Venezuelan equine encephalitis virus (VEEV) replicons that
express either GP or NP of MARV Musoke protected guinea pigs
from viremia and death caused by GP-adapted MARV challenge
(Hevey et al., 1998). Cynomolgus macaques administrated with
MARV Musoke GP-expressing VEEV replicons alone or in com-
bination with NP were also protected from lethal infection with
the homologousMusoke strain, but not from heterologous RAVV
(Hevey et al., 1998; Falzarano et al., 2011). additionally, vaccina-
tion with NP alone prevented death but not disease onset in two
of three monkeys and allowed all animals to become viremic. For
EBOV, EBOV GP-expressing VEEV replicons, alone or in com-
bination with EBOV NP-expressing VEEV replicons, protected
mice, and guinea pigs from lethal infection, whereas immuniza-
tion with EBOV NP-expressing VEEV replicons alone protected
mice but not guinea pigs (Pushko et al., 2001). Furthermore,
vaccination with recombinant VEEV, expressing EBOV GP, NP,
or both GP and NP, failed to protect cynomolgus macaques
from a lethal EBOV infection (Geisbert et al., 2002). One
recent study produced different results, whereby a VEEV-based
vaccine was fully protective in cynomolgus macaques against
EBOV, SUDV, and MARV (Friedrich et al., 2012). The results
obtained from these studies are inconsistent, suggesting that
VEEV-based vaccine may be promising although further research
is needed.
ADENOVIRUS-BASED VACCINES
Adenovirus (AdV) vectors commonly used are based on serotype
5 (AdV5). A single infection of the recombinant MARV Angola
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GP-expressing AdV5 resulted in complete protection of cynomol-
gus macaques from illness and death by challenge with homolo-
gous virus (Geisbert et al., 2010a). Vaccination with a mixture of
EBOV GP—expressing AdV5 and EBOV NP—expressing AdV5
have demonstrated 100% protection in cynomolgus macaques
against homologous virus challenge (Sullivan et al., 2003).
However, the genome insert size in this first generation AdV
vector was restricted to as little as a single filovirus GP gene.
The second generation AdV vector has the advantage of being
able to express multiple antigens in a single construct over the
first generation vector. The second generation bivalent AdV vec-
tor expressing GPs of EBOV and SUDV led to efficient induc-
tion of antibodies specific to EBOV and SUDV (Wang et al.,
2006b). A trivalent AdV vector expressing MARV GPs of Ci67,
Musoke and RAVV efficiently led to MARV-specific antibodies in
mice and guinea pigs and showed complete protection of guinea
pigs against MARV and RAVV infections (Wang et al., 2006a).
Additionally, vaccination of cynomolgus macaques with second
generation AdV vectors, which expressed multiple filovirus GPs
of EBOV, SUDV, Ci67, Musoke, and RAVV, induced 100% pro-
tection against challenge with EBOV and SUDV and two different
strains of MARV (Ci67 and Musoke; Swenson et al., 2008a).
Although the AdV-based vaccines showed efficacy, the vaccines
have a major obstacle: the prevalence of pre-existing immunity
to AdV that may substantially limit their immunogenicity and
clinical utility. It is estimated that the prevalence of antibody
to AdV5 is up to 60% in the general human population and
up to 85% in Africa (Schulick et al., 1997; Piedra et al., 1998).
Indeed, macaques pre-immunized against AdV5 and vaccinated
with EBOV GP-expressing AdV5 were not protected from lethal
challenge with EBOV infection (Geisbert et al., 2010b). AdV
serotype 26 and 35 segregated genetically from AdV5 exhibit
lower seroprevalence in humans (Vogels et al., 2003; Abbink
et al., 2007; Mast et al., 2010). Therefore, AdV serotype 26
and 35 vectors with expression of EBOV or SUDV GPs have
been generated and the protective efficacy examined by using
the NHP model, but these vectors failed to protect cynomol-
gus macaques against lethal EBOV challenge (Geisbert et al.,
2011).
DNA
The plasmid coding the DNA of GP from MARV Musoke or
RAVV demonstrated efficacy in protection of guinea pigs and
cynomolgus macaques against lethal infection of each homol-
ogous strain (Riemenschneider et al., 2003). All of the guinea
pigs vaccinated three or four times with DNA vaccines were
aviremic and appeared healthy. In cynomolgus macaques, four
of six monkeys immunized with 3 doses of DNA vaccine encod-
ing Musoke GP were protected from homologous challenge with
MARV Musoke (Riemenschneider et al., 2003). In a report of
DNA vaccines encoding GP of MARV Angola strain, the 4 vac-
cination doses resulted in protection of all four vaccinated mon-
keys, but three of the four monkeys showed symptoms and/or
lymphopenia (Geisbert et al., 2010a). A combination vaccine reg-
imen (3 times injection with DNA and boost with recombinant
Angola GP-expressing AdV vector) protected the monkeys from
lethal infections but two of the four monkeys showed rash or
lymphopenia. A single inoculation with AdV vaccine induced
optimal immune responses to eliminate symptoms and death
by itself. These data suggest that DNA vaccines do not opti-
mally control MARV infection (Geisbert et al., 2010a). However,
three-plasmid DNA vaccines encoding EBOV GP, SUDV GP, and
EBOV NP were evaluated in a phase I trial as safe and immuno-
genic in humans (Martin et al., 2006). The EBOV DNA vaccine
also protected mice and guinea pigs against a lethal challenge
(Vanderzanden et al., 1998; Xu et al., 1998; Martin et al., 2006).
In one study, cynomolgus macaques, which received 3 injections
of DNA vectors encoding EBOV GP, SUDV GP, TAFV GP, and
EBOV NP, were boosted with recombinant EBOV GP-expressing
AdV (Sullivan et al., 2000). All four monkeys vaccinated survived
and showed no symptoms of EBOV infection. This prime-boost
strategy provided a sufficient immune response to clear the virus
efficiently.
HUMAN PARAINFLUENZA VIRUS
In an outbreak of RESTV in the Hazleton facility in Reston,
Virginia, aerosol transmission between NHPs may have occurred
(Jahrling et al., 1990; Dalgard et al., 1992; Miranda et al.,
1999, 2002). To address the assumed aerosol transmission of
filovirus, a vaccine that induces a strong immune response
in the respiratory tract was developed. Human parainfluenza
virus type 3 (HPIV3), a common respiratory virus, was mod-
ified as a form of vaccine vector and used for development
of a vaccine against EBOV. The HPIV3 vectors, which express
EBOV GP or EBOV GP together with NP, protected guinea
pigs and rhesus macaques against EBOV challenge (Bukreyev
et al., 2006, 2007). In guinea pigs, a single intranasal inocu-
lation with HPIV3 expressing EBOV GP or both GP and NP
showed complete protection against signs of illness and death
(Bukreyev et al., 2006). The rhesus macaques were immunized
with a single dose of EBOV GP-expressing HPIV3, or EBOV
GP and NP-expressing HPIV3, through a combined intranasal
and intratracheal inoculation. Five of six monkeys immunized
with the HPIV3 based vaccine survived and four of six mon-
keys did not show any clinical illness (Bukreyev et al., 2007).
Two doses of intranasal immunizations showed greater effi-
cacy, including complete protection of all three rhesus macaques
against clinical illness and death. However, HPIV3 may not
be effective as a vaccine vectors in humans, since HPIV3 is a
common childhood pathogen and the majority of the popula-
tion have pre-existing immunity to HPIV3. To overcome the
problem of pre-existing immunity, a chimeric HPIV3, where
both HPIV3 surface proteins, HN and F, were deleted and
replaced with EBOV GP was developed (Bukreyev et al., 2009).
A single immunization with the vaccine completely protected
guinea pigs against a lethal infection. It was shown that the
HPIV3 based vaccine, which expressed EBOV GP, was immuno-
genic equally among HPIV3-naïve and HPIV3 antibody-positive
subjects and effective when vaccinated twice. However, pre-
existing HPIV3-specific immunity in rhesus macaques reduced
the replicative capacity of the HPIV3-based vaccine in the res-
piratory tract (Bukreyev et al., 2010). Nevertheless, this study
indicated that the vaccination induced an appropriate antibody
response.
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VESICULAR STOMATITIS VIRUS
A vaccine to resolve the problem of pre-existing immunity
utilized the recombinant vesicular stomatitis virus (VSV) vec-
tor, which expresses filovirus GP. VSV is mainly a veterinary
pathogen and human infection with VSV is rare and not associ-
ated with disease in humans. A single intramuscular vaccination
of cynomolgus macaques with recombinant VSV with expres-
sion of MARV Musoke GP elicited complete protection against
a high dose (103 pfu) intramuscular challenge with both homolo-
gous Musoke strain and heterologous Popp strain, Angola strain,
and RAVV (Jones et al., 2005; Daddario-Dicaprio et al., 2006a).
For EBOV, a single immunization of cynomolgus macaques with
recombinant VSV vector, which expresses EBOV GP, also elicited
complete protection against EBOV challenge (Jones et al., 2005).
The surviving macaques from lethal EBOV infection were re-
challenged with heterologous SUDV, but the cross-protection was
not observed (Jones et al., 2005). Administration of the EBOV
GP-expressing VSV vaccine through the oral or intranasal route
completely protected cynomolgus macaques from EBOV chal-
lenge (Qiu et al., 2009). A blended vaccine consisting of equal
amounts of 3 different VSV vectors, which expresses GP of each
of EBOV, SUDV, and MARV, generated complete protection of
cynomolgus macaques against challenges with EBOV, TAFV, and
MARV (Geisbert et al., 2009). Macaques vaccinated with the
blended vaccine followed by challenge with SUDV showed mild
clinical sign of illness including fever, lymphopenia, and mild
anorexia, and the macaques recovered from illness. Importantly,
none of the macaques vaccinated with the blended vaccine suc-
cumbed to a filovirus challenge. The efficacy of the recombinant
VSV vaccine has been evaluated as a post-exposure prophy-
laxis for filovirus infections. Administration of recombinant VSV
with MARV Musoke GP expression to rhesus macaques shortly
after a homologous high-dose MARV challenge resulted in com-
plete protection of all subjects from clinical illness and death
(Daddario-Dicaprio et al., 2006b). Furthermore, administration
of recombinantMARVMusokeGP-expressing VSV at 24 and 48 h
following infection resulted in protection of 83 and 33% of rhesus
macaques, respectively (Geisbert et al., 2010c). When recombi-
nant EBOV GP-expressing VSV were administrated to mice 24 h
prior to challenge, and 1 and 24 h post-challenge, all treated mice
survived (Feldmann et al., 2007). In guinea pigs treated with
EBOVGP-expressing VSV at 24 h prior to challenge, and 1 or 24 h
post-challenge, the survival rates were 67, 83, and 50%, respec-
tively. It was also demonstrated that post-exposure vaccination
with the recombinant VSV GP vectors for EBOV and SUDV in
rhesus macaques was effective against challenge with homologous
viruses, although the protection rate was dependent on the species
of ebolavirus. The survival rates of the EBOV- or SUDV-infected
monkeys were 50 and 100%, respectively (Feldmann et al., 2007;
Geisbert et al., 2008).
VIRUS-LIKE PARTICLE
Virus-like particle (VLPs), which mimic authentic virions struc-
turally but do not contain infectious genetic material, are non-
infectious and safer than replicating vaccines. The efficiency of
a MARV vaccine consisting of VLPs with MARV Musoke GP
and VP40 was assessed in guinea pig and cynomolgus macaque
models (Swenson et al., 2008b). The guinea pigs and monkeys
immunized three times with MARV-Musoke VLPs with RIBI or
QS-21 adjuvant were challenged with Musoke strain, Ci67 strain,
or RAVV. All guinea pigs and eight monkeys were protected from
death and clinical illness following the lethal challenge, except for
a single monkey. The monkey challenged with RAVV, which is
the most genetically distinct strain of marburgvirus, developed
minor signs of disease without detectable viremia. For ebolavirus,
mice vaccinated with EBOV VLP in the presence or absence of
adjuvant were protected from lethal EBOV infection in a dose-
dependent manner (Warfield et al., 2003, 2007a; Sun et al., 2009).
Furthermore, the efficacy of the EBOV VLP, which consists of
EBOV GP, NP, and VP40 was evaluated in cynomolgus macaques
(Warfield et al., 2007b). All five monkeys that received three injec-
tions of the EBOV VLPs with RIBI adjuvant were completely
protected against EBOV challenge.
There are some other vaccine candidates, including an EBOV
lacking VP30 (which encodes the essential transcription factor),
an Fc portion of a human IgG fused to EBOV-GP, a bean yel-
low dwarf virus-derived replicon system, and a cytomegalovirus-
based vaccine encoding an EBOV NP CTL epitope (Halfmann
et al., 2009; Konduru et al., 2011; Phoolcharoen et al., 2011; Tsuda
et al., 2011a). However, the immunogenic efficacy of these vac-
cines has only been confirmed in the rodent models and further
studies are needed to evaluate the protective efficacy and safety in
NHPs.
TREATMENTS
RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2
Coagulation abnormalities are one of the most prominent hall-
marks of filovirus infection. It has been suggested that tissue
factor plays an important role in triggering the hemorrhagic
complications in NHPs infected with filoviruses (Geisbert et al.,
2003d). Overexpression of tissue factor that performs as the pri-
mary cellular inhibitor of the coagulation protease cascades is
one of the causes of DIC and thrombosis-related organ failure.
The effect of blocking the pathway leading from the complex
of activated factor VII and tissue factor to thrombin was exam-
ined in filovirus infection. Recombinant nematode anticoagulant
protein c2 (rNAPc2), which directly inhibits factor VII and tis-
sue factor, provided partial post-exposure protection to rhesus
macaques infected with filovirus (Geisbert et al., 2003a, 2009). In
rNAPc2-treated rhesus macaques, the mean survival time (11.7
days) was longer than that in untreated control monkeys (8.3
days) and 33% of EBOV-infected macaques survived. In MARV
Angola-infected rhesus macaques treated with rNAPc2, 1 of 6
(17%) monkeys survived and the mean survival time for the
five dead monkeys was significantly prolonged compared with
that of the untreated control monkeys. rNAPc2 demonstrated a
clear improvement in terms of survival rate and an increase in
mean survival time in a normally 100% lethal model of filovirus
infection.
RECOMBINANT HUMAN ACTIVATED PROTEIN C
Activated protein C (APC) is generated from the protein C, which
is a vitamin K-dependent plasma protein and inactivates fac-
tors V and VIII to down-regulate thrombin generation. It has
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been reported that circulating levels of protein C were rapidly
and significantly reduced in cynomolgus macaques and rhesus
macaques during EBOV infections, because the protein C might
be produced in the liver, which is a main target of filovirus infec-
tion (Geisbert et al., 2003a). In rhesus macaque models, adminis-
tration of recombinant human APC (rhAPC) at 30–60min after
challenge and continuing for 7 days, protected 2 of 11 (18%)
monkeys against lethal EBOV infection (Hensley et al., 2007).
The mean survival time in the rhAPC-treated monkeys was pro-
longed compared with the untreated monkeys (Hensley et al.,
2007).
PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER
Phosphorodiamidate morpholino oligomers (PMOs) inhibit tar-
geted gene translation by steric blockage of ribosomal assembly. A
combination of EBOV-specific PMOs targeting sequences of viral
mRNAs for the VP24, VP35, and RNA polymerase L protected
rodents in both pre- and post-exposure therapeutic regimens
(Warfield et al., 2006). In rhesus macaquemodels, treatment with
a combination of the PMOs of VP24, VP35, and L from 2 days
prior to EBOV challenge through Day 9 of the infection protected
3 of 4 (75%) rhesus macaques against lethal infection (Warfield
et al., 2006). Furthermore, it was demonstrated that the antiviral
potency of PMOs could be enhanced by chemical modification,
either by conjugating PMOs with peptides or by introducing pos-
itively charge to the PMOs (PMOplus™, Avi BioPharma, Inc.;
Swenson et al., 2009). Subsequently, PMOplus targeting EBOV
VP24 and VP35 or MARV Musoke VP24 and NP showed signifi-
cant protection of mice and guinea pigs against lethal challenge
with EBOV and MARV Musoke, respectively (Warren et al.,
2010). AVI-6002 PMOplus against both EBOV VP24 and VP35,
and AVI-6003 PMOplus against MARV VP24 and NP, were devel-
oped and tested for treatment efficacy using NHP models. These
PMOs, delivered 30–60min post-exposure, protected 62.5% of
rhesus macaques against lethal EBOV infection and 100% of
cynomolgus macaques against MARV Musoke infection (Warren
et al., 2010). AVI-6002 and AVI-6003 are currently in phase I
clinical trials.
RNA INTERFERENCE
RNA interference (RNAi) inhibits gene expression to the extent
that their function is abrogated through a highly regulated
enzyme-mediated process. It was demonstrated that small-
interfering RNA (siRNA) down-regulated various MARV mRNA
transcripts, resulting in a significant decrease in viral protein pro-
duction and subsequent viral release in vitro (Fowler et al., 2005).
Furthermore, siRNA targeting the EBOV RNA polymerase L pro-
tein formulated in stable nucleic acid-lipid particles (SNALPs)
completely protected guinea pigs when administered shortly
after a lethal EBOV infection (Geisbert et al., 2006). In rhesus
macaques, a combination of siRNA targeting the EBOV L, VP24,
and VP35 were formulated in SNALPs and administrated to the
monkeys. Two of three monkeys, which were treated four times
with siRNA at 30min, 1, 3, and 5 days after challenge, survived
lethal infection. Furthermore, all four monkeys treated seven
times at 30min, 1–6 days after challenge survived (Geisbert et al.,
2010d).
THERAPEUTIC EFFICACY IN THE MOUSE MODEL AND in vitro
In the mouse model, administration of recombinant mannose-
binding lectin and hexaamminecobalt (III) chloride showed effi-
cacy in protecting against EBOV infections (Michelow et al.,
2011). Mannose-binding lectin targets diverse microorganisms
for phagocytosis and complement-mediated lysis by binding spe-
cific surface glycans. Hexaamminecobalt (III) chloride is a com-
plex of a cobalt (III) ion surrounded by six ammonia ligands in a
full octahedral coordination. Furthermore, by high-throughput
screening, some compounds such as FGI-103, FGI-106, and
NSC 62914 (a reactive oxygen species scavenger), were iden-
tified to have high antiviral activity against filoviruses (Aman
et al., 2009; Warren et al., 2010). Some other substances, for
example inhibitors of heat-shock protein 90 and Niemann-Pick
C1, showed antiviral activity in vitro (Smith et al., 2010; Cote
et al., 2011). As mentioned above (Table 3), several candidates
are discussed as therapeutic agents for Ebola and Marburg HFs,
but no licensed therapeutics are yet available (Friedrich et al.,
2012).
CONCLUSIONS
Significant progress has been made in developing animal models,
including mice, guinea pigs, hamsters and NHPs, for EHF and
MHF. The NHPs are the most feasible model, because they are
the only animals that are lethally infected with non-adapted virus
isolates and the pathophysiology is close to that demonstrated
in patients. The rodent models need serial passages of original
filoviruses in rodents for acquiring lethal infection capacity and
they have limited value, because the disease course in rodents
differs from that demonstrated in humans and NHPs. However,
the rodent models are the first choice for preliminary studies to
explore vaccines and therapeutic agents, because of their ease
to handling. The newly developed Golden hamster model will
also be used for studies on pathogenesis and evaluation of effi-
cacy of candidate vaccines and therapeutics because they show
manifestations similar to those of patients and NHPs, including
severity of coagulopathy that is lacking in mouse and guinea pig
models. Among the candidate vaccines so far developed, recom-
binant VSV-based vaccines against EHF and MHF are confirmed
to be effective in mouse, guinea pig, Golden hamster, and NHP
models, and are the only platform with the potential to prevent
lethal infection, especially via both vaccine and post-exposure
treatment (Jones et al., 2005; Daddario-Dicaprio et al., 2006b;
Feldmann et al., 2007; Geisbert et al., 2008, 2009, 2010c; Qiu
et al., 2009; Tsuda et al., 2011b). Furthermore, the VSV have
been used as a treatment following a recent laboratory exposure
(Tuffs, 2009). Further research is needed to develop vaccines with
sufficient long-term efficacy by single-dose vaccination, because
expensive and time-consuming vaccinations may pose difficulties
due to logistical and financial problems in developing countries,
where EHF and MHF are endemic. Neither licensed vaccines nor
therapeutic agents are available so far. The development of vac-
cines and therapeutic testing using the animal models has only
recently begun to progress. We hope that further research facili-
tates progress toward elucidating the disease pathophysiology and
developing prophylactic and therapeutic measures against EHF
and MHF.
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